Nuvation Bio Net Worth
Nuvation Bio Net Worth Breakdown | NUVB |
Nuvation Bio Net Worth Analysis
Nuvation Bio's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Nuvation Bio's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Nuvation Bio's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Nuvation Bio's net worth analysis. One common approach is to calculate Nuvation Bio's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Nuvation Bio's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Nuvation Bio's net worth. This approach calculates the present value of Nuvation Bio's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Nuvation Bio's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Nuvation Bio's net worth. This involves comparing Nuvation Bio's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Nuvation Bio's net worth relative to its peers.
To determine if Nuvation Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Nuvation Bio's net worth research are outlined below:
| Nuvation Bio generated a negative expected return over the last 90 days | |
| Nuvation Bio has high historical volatility and very poor performance | |
| Nuvation Bio may become a speculative penny stock | |
| The company reported the previous year's revenue of 7.87 M. Net Loss for the year was (567.94 M) with profit before overhead, payroll, taxes, and interest of 795 K. | |
| Nuvation Bio currently holds about 703.8 M in cash with (130.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Nuvation Bio has a frail financial position based on the latest SEC disclosures | |
| Roughly 59.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Is Nuvation Bio Inc. the Most Oversold Penny Stocks to Buy According to Analysts |
Nuvation Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Nuvation Bio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Nuvation Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Nuvation Bio Target Price Consensus
Nuvation target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Nuvation Bio's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 4 | Strong Buy |
Most Nuvation analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Nuvation stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Nuvation Bio, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationNuvation Bio Target Price Projection
Nuvation Bio's current and average target prices are 1.96 and 7.50, respectively. The current price of Nuvation Bio is the price at which Nuvation Bio is currently trading. On the other hand, Nuvation Bio's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Nuvation Bio Target Price
Follow Nuvation Bio's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 707.84 M.Market Cap |
|
Project Nuvation Bio's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.06) | (1.11) | |
| Return On Capital Employed | (1.23) | (1.17) | |
| Return On Assets | (1.05) | (1.10) | |
| Return On Equity | (1.22) | (1.16) |
When accessing Nuvation Bio's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Nuvation Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Nuvation Bio's profitability and make more informed investment decisions.
Please note, the presentation of Nuvation Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Nuvation Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Nuvation Bio's management manipulating its earnings.
Evaluate Nuvation Bio's management efficiency
Nuvation Bio has return on total asset (ROA) of (0.1802) % which means that it has lost $0.1802 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0627) %, meaning that it created substantial loss on money invested by shareholders. Nuvation Bio's management efficiency ratios could be used to measure how well Nuvation Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of March 19, 2025, Return On Tangible Assets is expected to decline to -1.11. The current year's Return On Capital Employed is expected to grow to -1.17. At present, Nuvation Bio's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Assets is expected to grow to about 541.4 M, whereas Total Current Assets are forecasted to decline to about 459.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.73 | 1.61 | |
| Tangible Book Value Per Share | 1.71 | 1.60 | |
| Enterprise Value Over EBITDA | (1.21) | (1.27) | |
| Price Book Value Ratio | 1.54 | 1.62 | |
| Enterprise Value Multiple | (1.21) | (1.27) | |
| Price Fair Value | 1.54 | 1.62 |
The leadership approach at Nuvation Bio's fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nuvation Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nuvation Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Nuvation Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Nuvation Bio Corporate Filings
8K | 6th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 12th of February 2025 Other Reports | ViewVerify | |
F4 | 13th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Nuvation Bio Earnings per Share Projection vs Actual
Nuvation Bio Corporate Management
| W Vernon | Independent Director | Profile | |
| Michelle Doig | Independent Director | Profile | |
| Gary Hattersley | Chief Scientific Officer | Profile | |
| Moses Makunje | Principal Officer | Profile | |
| Robert Bazemore | Independent Director | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nuvation Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Nuvation Stock refer to our How to Trade Nuvation Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nuvation Bio. If investors know Nuvation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nuvation Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Nuvation Bio is measured differently than its book value, which is the value of Nuvation that is recorded on the company's balance sheet. Investors also form their own opinion of Nuvation Bio's value that differs from its market value or its book value, called intrinsic value, which is Nuvation Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nuvation Bio's market value can be influenced by many factors that don't directly affect Nuvation Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nuvation Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nuvation Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nuvation Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.